Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
One-third of preterm infants are diagnosed with bronchopulmonary dysplasia (BPD), a complex multifactorial disorder associated with significant morbidity. Associated pathologies include pulmonary hypertension (PH), a critical cardiorespiratory pathology with 48% 2-year mortality that affects up to a third of infants with BPD.1 Pulmonary vasodilatation in PH prolongs life, and phosphodiesterase-V inhibition is the primary approach for this.2 That stated, current evidence is limited to 45 patients across five case series.3 They demonstrate a reduction in overall mortality to 18%, but reservations remain regarding safety and efficacy.
We therefore conducted a retrospective investigation into patients with BPD–PH managed at our centre between August 2008 and July …
Contributors All authors made substantial contributions to the conception of the work and the acquisition, analysis or interpretation of data; drafted the work and approved the version submitted for publication.
Competing interests None.
Provenance and peer review Not commissioned; internally peer reviewed.